J3M-MC-JZQB
1+
Downloads
Everyone
info
About this app
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
No data collected
Learn more about how developers declare collection
Data is encrypted in transit
What's new
Initial release
App support
About the developer
Medable Inc.
tim@medable.com
525 University Ave Ste A70
Palo Alto, CA 94301
United States
+1 650-231-5478
